Boston Life Sciences Gets Spinal Cord Candidate Via Licensing Deal
This article was originally published in The Pink Sheet Daily
Cethrin represents “a new generation of drugs” to treat central nervous system injuries, exec says.
You may also be interested in...
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.
Exec discusses the firm’s pulmonary arterial hypertension drug Tracleer and other endothelin receptor antagonists in Actelion’s pipeline.
Bayer Schering Pharma SVP-Global Business Development And Licensing Michael Yeomans: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Yeomans discusses how the firm’s increasing biologics capabilities fits into Bayer Schering’s business development strategy and the growing importance of Asia to the company.